Bausch Health Announces 2021 Annual Meeting of Shareholder Results

 
 

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company") today announced the election of the 13 directors nominated at its 2021 annual meeting of shareholders held on April 27, 2021 . The detailed results of the vote for the election of directors are set out below:

 
 
                                                        
 

   Name   

 
 

   For   

 
 

   Withheld   

 
 

   Broker Non-Votes   

 
 

  Richard U. De Schutter  

 
 

  200,369,606  

 
 

  5,768,489  

 
 

  60,380,196  

 
 

  D. Robert Hale  

 
 

  196,356,636  

 
 

  9,781,459  

 
 

  60,380,196  

 
 

  Brett Icahn  

 
 

  196,491,749  

 
 

  9,646,346  

 
 

  60,380,196  

 
 

  Dr. Argeris (Jerry) N. Karabelas  

 
 

  198,928,372  

 
 

  7,209,723  

 
 

  60,380,196  

 
 

  Sarah B. Kavanagh  

 
 

  203,110,562  

 
 

  3,027,533  

 
 

  60,380,196  

 
 

  Steven D. Miller  

 
 

  200,857,243  

 
 

  5,280,852  

 
 

  60,380,196  

 
 

  Joseph C. Papa  

 
 

  198,455,884  

 
 

  7,682,211  

 
 

  60,380,196  

 
 

  John A. Paulson  

 

 

  205,191,567  

 
 

  946,528  

 
 

  60,380,196  

 
 

  Robert N. Power  

 
 

  177,088,588  

 
 

  29,049,507  

 
 

  60,380,196  

 
 

  Russel C. Robertson  

 
 

  197,810,980  

 
 

  8,327,115  

 
 

  60,380,196  

 
 

  Thomas W. Ross, Sr.  

 
 

  186,746,866  

 
 

  19,391,229  

 
 

  60,380,196  

 
 

  Andrew C. von Eschenbach, M.D.  

 
 

  205,016,196  

 
 

  1,121,899  

 
 

  60,380,196  

 
 

  Amy B. Wechsler, M.D.  

 
 

  200,266,488  

 
 

  5,871,607  

 
 

  60,380,196  

 
 
 

At the annual meeting of shareholders, shareholders also approved in a non-binding advisory vote the compensation of the Company's named executive officers and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2022 annual meeting of shareholders.

 

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's website at www.bauschhealth.com .

 

  About Bausch Health  

 

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com .

 
 
          
 

   Investor Contact:   

 
 

   Media Contact:   

 
 

  Arthur Shannon  

 
 

  Lainie Keller  

 
 

   arthur.shannon@bauschhealth.com   

 
 

   lainie.keller@bauschhealth.com   

 
 

  (514) 856-3855  

 
 

  (908) 927-1198  

 
 

  (877) 281-6642 (toll free)  

 
 
 
 

 

 
 

  Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.) 

 
 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch-health-announces-2021-annual-meeting-of-shareholder-results-301278480.html  

 

SOURCE Bausch Health Companies Inc.

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Bausch Health Companies Inc.

Bausch Health Companies Inc.

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.

illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×